NBI-1117568

Neurocrine randomizes first patient in Phase II schizophrenia therapy trial
Clinical Trials Arena
Fri, 10/28/22 - 10:28 am
Neurocrine Biosciences
clinical trials
NBI-1117568
schizophrenia